Addition Therapeutics unveiled its Precise RNA‑Mediated Insertion of Transgenes (PRINT) platform, an all‑RNA, lipid‑nanoparticle (LNP) approach to genomic insertion based on retrotransposon biology from Kathleen Collins’ lab at UC Berkeley. The company argues the method can insert therapeutic payloads into a defined genomic safe site without DNA vectors. Addition positioned PRINT as an alternative to viral vectors and permanent genome editing, emphasizing a potentially safer insertion profile and scalability via LNP delivery. The company emerged from stealth alongside significant financing to progress preclinical programs. Financially, Addition disclosed a large funding package to scale the platform and recruit development talent, signaling investor appetite for novel gene‑insertion strategies. The approach will be scrutinized for insertion fidelity, off‑target activity, and immunogenicity as it advances toward the clinic.